Kenvue stands out as an attractive high-yield healthcare dividend stock, especially for income-focused investors looking for relatively predictable returns amid market volatility and economic uncertainty. The company has raised its dividend for 64 consecutive years, earning it the status of Dividend King. Its 4.68% yield is more than four times the average S&P 500 dividend yield.
Kenvue's portfolio includes recession-resilient brands such as Tylenol, Motrin, Listerine, Band-Aid, Neutrogena, and Zyrtec, which support steady consumer demand. In the second quarter, Kenvue reported revenue of $3.95 billion, up 3% year over year, while earnings per share rose 9% to $0.24. The main uncertainty is Kimberly-Clark’s planned acquisition of Kenvue, which could affect its dividend structure if approved.
Kimberly-Clark also has a strong dividend record, with 54 consecutive years of increases and a yield around 5.23%. The proposed combination may offer greater scale and cost savings, while Kenvue’s financial performance, strong brands, and dividend history continue to make it notable for investors seeking income and long-term returns.
